Lipodystrophy syndrome in HIV treatment-multiexperienced patients: implication of resistin
Lipodystrophy syndrome in HIV treatment-multiexperienced patients: implication of resistin
复制标题
DOI：
10.1007/s40618-014-0057-x
复制
发表时间：
2014-06-01
影响因子：
5.4
通讯作者：
Arama, S. S.
中科院分区：
文献类型：
--
作者：
Arama, V.;Munteanu, D. I.;Arama, S. S.
脂肪细胞因子的产生受损是导致脂肪营养不良 (LD) 发生的一个主要因素。旨在评估多次接受 HIV 治疗的患者中 LD 的患病率和亚型，并确定脂肪细胞因子与 LD 亚型之间的相关性。2008 年至 2010 年间，在罗马尼亚三级护理医院对 HIV 阳性患者进行横断面研究， cART 为千分之一日元6 个月。 LD诊断基于临床和人体测量数据，分为脂肪萎缩（LA）、脂肪肥大（LH）和混合脂肪再分布（MFR）。采集血样进行瘦素、脂联素和抵抗素评估。我们纳入了 100 名患者，其中 44% 患有 LD，其中 LA 占 63%。与非 LD 患者相比，LA 患者的性别比、中位年龄、治疗持续时间和 ARV 治疗方案中位次数分别为 1、20、93 和 3.5：1.65、31、44 和 1。与非 LD 患者相比，LH 和 MFR 患者年龄较大，总胆固醇和 LDL 胆固醇较高。对于整体组和女性组，单变量和多变量分析中，LA 与抵抗素增加（p = 0.02 和 0.04）和 ARV 治疗方案数量（p < 0.001）相关。 LA 存在时抵抗素增加和 ARV 组合数量的决定系数 (Nagelkerke R (2)) 在整个组中为 33%，在女性患者中为 47%。 在我们年轻的 HIV 阳性人群中，LD 的患病率很高，其中 LA 亚型占主导地位。在整个组和女性亚组中，LA 与高抵抗素水平和更多的 ARV 治疗方案相关。抵抗素可用作外周脂肪组织损失的标志物，并可用作新的抗 LD 治疗策略的靶标。
Impaired production of adipocytokines is a major factor incriminated in the occurrence of lipodystrophy (LD).To evaluate LD prevalence and subtypes in HIV treatment-multiexperienced patients, and to determine the correlations between adipocytokines and LD subtypes.Cross-sectional study in a Romanian tertiary care hospital, between 2008 and 2010, in HIV-positive patients, undergoing cART for a parts per thousand yen6 months. LD diagnosis, based on clinical and anthropometric data, was classified into lipoatrophy (LA), lipohypertrophy (LH) and mixed fat redistribution (MFR). Blood samples were collected for leptin, adiponectin and resistin assessments.We included 100 patients, 44 % with LD, among which LA had 63 %. LA patients had sex ratio, median age, treatment duration and median number of ARV regimens of 1, 20, 93 and 3.5 compared to non-LD patients: 1.65, 31, 44 and 1. LH and MFR patients were older and had higher total and LDL cholesterol versus non-LD patients. For both overall group and female group, LA was associated in univariate and multivariate analysis with increased resistin (p = 0.02 and 0.04) and number of ARV regimens (p < 0.001). Determination coefficient (Nagelkerke R (2)) of increased resistin and the number of ARV combinations in the presence of LA was 33 % in overall group and 47 % in female patients.In our young HIV-positive population, LD had high prevalence with predominance of LA subtype. LA was associated with high resistin levels and greater number of ARV regimens in overall group and female subgroup. Resistin could be used as a marker of peripheral adipose tissue loss and might be used as a target for new anti-LD therapeutic strategies.